AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02044861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFK-158
Description: IV dose escalation
Study NCT00971295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
Study NCT00971295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Study NCT01506284 — intervention group
Intervention type: PROCEDURE
Intervention: Forced oscillatory technique (FOT) and laser interferometry (LIR).
Description: FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient.
Study NCT02597140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
Study NCT02597140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
Study NCT02597140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
Study NCT02597140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
Study NCT04484207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A short video intervention
Description: Three minutes video of a veteran that shares his personal story
Study NCT04484207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A vignette intervention
Description: A written description of the content of the video
Study NCT03899051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interdental papilla reconstructive surgery with PRF
Description: Papilla reconstruction would be done with platelet rich fibrin
Study NCT03899051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interdental papilla reconstructive surgery with subepithelial connective tissue graft
Description: Papilla reconstruction would be done with subepithelial connective tissue graft
Study NCT00952900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biobehavioral
Description: 6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
Study NCT00952900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Coping/Attention Intervention
Description: 6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
Study NCT00859157 — intervention group
Intervention type: PROCEDURE
Intervention: therapeutic conventional surgery
Description: Patients undergo tumescent or standard mastectomy
Study NCT03881904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075mg gestodene/0.03mg ethinylestradiol
Description: OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
Study NCT02161757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Subcutaneous injection
Study NCT02161757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT02588209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic Memory Advanced Reasoning Training
Description: SMART teaches strategies to improve the ability to process information.
Study NCT02588209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Workshop
Description: Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
Study NCT01323140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone matrix transdermal system
Study NCT01452503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Path Women's Condom
Description: comparison between 3 types of female condoms
Study NCT01452503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FC2 female condom
Description: comparison between 3 types of female condoms
Study NCT01452503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reddy 6 female condom (V-Amour)
Description: comparison between 3 types of female condoms
Study NCT04510103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moisturizer A, F#9155-005
Description: OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
Study NCT04510103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Moisturizer B, F#E1387-004
Description: Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
Study NCT03805932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
Study NCT04510103 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regression
Description: 2 week regression period after 6 weeks of moisturizer use.
Study NCT04510103 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-Regression
Description: Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
Study NCT03589222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
Study NCT03589222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
Study NCT01865695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon
Description: Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
Study NCT01865695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03589222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
Study NCT03589222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
Study NCT02332291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10-20mg daily
Study NCT02332291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL
Description: Bupropion XL 150-450mg daily
Study NCT02332291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion XL
Description: Bupropion XL 150-450mg daily
Study NCT02376803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Morning vs Evening administration
Study NCT02376803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Morning vs Evening administration
Study NCT03360058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Talk Big Difference Immediate access training
Description: Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
Study NCT03360058 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Small Talk Big Difference delayed access training
Description: Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
Study NCT00467233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Treatment
Description: Laser treatment to half of the face at each study visit
Study NCT00467233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acid Peel
Description: Acid peel to half of the face at each study visit
Study NCT02690441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
Study NCT02690441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
Study NCT02690441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
Study NCT02690441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo control
Description: One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
Study NCT02747368 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ocusweep system
Description: Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
Study NCT00559988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home Monitoring Guided OAC
Description: Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
Study NCT00559988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician-Directed OAC
Description: Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
Study NCT01178424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
Study NCT01178424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
Study NCT01032031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea + vitamin C high dose
Description: One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
Study NCT01032031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: One capsule daily for 3 months
Study NCT03286816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SodiumChloride
Study NCT03286816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Study NCT02567045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: annual FIT and colonoscopy in case of a positive test
Description: FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
Study NCT02567045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy with sedation
Description: One-time Colonoscopy with sedation.
Study NCT02567045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy with sedation
Description: One-time Colonoscopy with sedation.
Study NCT04346849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
Study NCT02457949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-synchronized social assistance receipt
Description: Social assistance disbursement outside government cheque issue week
Study NCT01196065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: single oral dose
Study NCT01196065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: multiple doses to steady state
Study NCT02817386 — intervention group
Intervention type: OTHER
Intervention: interview
Description: Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
Study NCT01970527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01970527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01970527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01970527 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT03249857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive tasks + IQ + MINI
Description: Patients will perform different tasks:~* cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~* Intelligence Quotient (IQ) test (PM38, Raven, 1960)~* Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)
Study NCT03249857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tasks
Description: Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
Study NCT02671786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAHAN RUTF & MAHAN Vit-Min mix
Description: MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
Study NCT02457949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cheque divided into two equal disbursements
Description: Social assistance disbursement divided into two equal payments
Study NCT02673684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental NSS
Description: 5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
Study NCT02673684 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NSS
Description: (5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
Study NCT02119390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff-delivered intervention sessions
Description: In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
Study NCT02119390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic Questionnaire
Description: Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
Study NCT02119390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Demographic Questionnaire
Description: Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
Study NCT02119390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
Study NCT03890770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration
Study NCT03020823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB01A
Description: intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02952027 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Use-recording, patient-reminder alarm for incentive spirometry
Study NCT04103632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EVH test
Description: * Spirometry~* Skin prick test~* Peripheral blood test~* FeNO measurement
Study NCT02631863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid
Description: Aminolaevulinic acid with illumination
Study NCT02119390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
Study NCT02409342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Description: Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
Study NCT02409342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
Study NCT02409342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.
Study NCT02409342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
Study NCT02409342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).